In HER2-positive breast cancer, understanding tumour biology has been crucial to identify those patients at higher risk of BM development and therefore worthy of special surveillance, such as central nervous system periodic scan, for early diagnosis and treatment. This evidence concerns the gene ERBB2 and breast carcinoma.